DB:O7PA

Stock Analysis Report

Executive Summary

OHR Pharmaceutical, Inc. operates as a development stage pharmaceutical company.


Snowflake Analysis

Adequate balance sheet and overvalued.

Share Price & News

How has OHR Pharmaceutical's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: O7PA's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

30.2%

O7PA

11.2%

DE Biotechs

7.3%

DE Market


1 Year Return

20.2%

O7PA

-5.1%

DE Biotechs

-17.7%

DE Market

Return vs Industry: O7PA exceeded the German Biotechs industry which returned 5.3% over the past year.

Return vs Market: O7PA exceeded the German Market which returned 17.1% over the past year.


Shareholder returns

O7PAIndustryMarket
7 Day30.2%11.2%7.3%
30 Day33.9%-5.3%-17.9%
90 Day80.1%-21.9%-25.8%
1 Year20.2%20.2%-4.9%-5.1%-15.1%-17.7%
3 Year-92.2%-92.2%17.7%16.5%-18.7%-25.6%
5 Year-97.0%-97.0%-5.1%-7.5%-17.7%-29.0%

Price Volatility Vs. Market

How volatile is OHR Pharmaceutical's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is OHR Pharmaceutical undervalued compared to its fair value and its price relative to the market?

1.55x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate O7PA's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate O7PA's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: O7PA is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: O7PA is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate O7PA's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: O7PA is good value based on its PB Ratio (1.6x) compared to the DE Biotechs industry average (3.4x).


Next Steps

Future Growth

How is OHR Pharmaceutical forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

58.0%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as OHR Pharmaceutical has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has OHR Pharmaceutical performed over the past 5 years?

-6.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: O7PA is currently unprofitable.

Growing Profit Margin: O7PA is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: O7PA is unprofitable, and losses have increased over the past 5 years at a rate of -6.4% per year.

Accelerating Growth: Unable to compare O7PA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: O7PA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (5.4%).


Return on Equity

High ROE: O7PA has a negative Return on Equity (-99.27%), as it is currently unprofitable.


Next Steps

Financial Health

How is OHR Pharmaceutical's financial position?


Financial Position Analysis

Short Term Liabilities: O7PA's short term assets ($2.3M) exceed its short term liabilities ($624.7K).

Long Term Liabilities: O7PA has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: O7PA is debt free.

Reducing Debt: O7PA has no debt compared to 5 years ago when its debt to equity ratio was 5.4%.


Balance Sheet

Inventory Level: O7PA has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if O7PA's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: O7PA has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: O7PA has less than a year of cash runway if free cash flow continues to grow at historical rates of 19.6% each year.


Next Steps

Dividend

What is OHR Pharmaceutical's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate O7PA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate O7PA's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if O7PA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if O7PA's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of O7PA's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.5yrs

Average management tenure


CEO

Jason Slakter (61yo)

3.83s

Tenure

US$389,574

Compensation

Dr. Jason Scott Slakter, M.D., has been the Chief Executive Officer and President of Ohr Pharmaceutical, Inc. since September 2015. Dr. Slakter is a Partner at Vitreous-Retina-Macula Consultants of New Yor ...


CEO Compensation Analysis

Compensation vs Market: Jason's total compensation ($USD389.57K) is about average for companies of similar size in the German market ($USD425.50K).

Compensation vs Earnings: Jason's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Jason Slakter
CEO, President & Director3.83yrsUS$389.57kno data
Samuel Backenroth
CFO, VP of Business Development & Secretary9.25yrsUS$370.15kno data
Glenn Stoller
Chief Scientific Officer5.08yrsno datano data
Marlene Modi
Head of Preclinical & Regulatory Affairs3.17yrsno datano data

4.5yrs

Average Tenure

55yo

Average Age

Experienced Management: O7PA's management team is considered experienced (4.5 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Jason Slakter
CEO, President & Director3.83yrsUS$389.57kno data
Thomas Riedhammer
Independent Director6.25yrsUS$83.83kno data
Orin Hirschman
Independent Director10.33yrsUS$116.41kno data
Lawrence Singerman
Member of Scientific Advisory Board7.08yrsno datano data
David Boyer
Member of Scientific Advisory Board7.08yrsno datano data
Jeffrey Heier
Member of Scientific Advisory Boardno datano datano data
June Almenoff
Independent Director6.17yrsUS$83.83kno data
Michael Elman
Member of Scientific Advisory Board7.17yrsno datano data
John Wroblewski
Member of Scientific Advisory Board5.92yrsno datano data
Michael Ferguson
Chairman of the Board2.17yrsUS$10.00kno data

6.3yrs

Average Tenure

59.5yo

Average Age

Experienced Board: O7PA's board of directors are considered experienced (6.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Insufficient data to determine if shareholders have been diluted in the past year.


Top Shareholders

Company Information

OHR Pharmaceutical, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: OHR Pharmaceutical, Inc.
  • Ticker: O7PA
  • Exchange: DB
  • Founded:
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$11.713m
  • Listing Market Cap: US$10.405m
  • Shares outstanding: 2.83m
  • Website: https://www.ohrpharmaceutical.com

Number of Employees


Location

  • OHR Pharmaceutical, Inc.
  • 800 Third Avenue
  • 11th Floor
  • New York
  • New York
  • 10022
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
OHRPNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDApr 2007
O7PADB (Deutsche Boerse AG)YesCommon StockDEEURApr 2007

Biography

OHR Pharmaceutical, Inc. operates as a development stage pharmaceutical company. The company intends to merge with NeuBase Therapeutics, Inc. that focuses on advancing NeuBase’s peptide-nucleic acid antisense oligonucleotide technology platform for the development of therapies to address severe and currently untreatable diseases caused by genetic mutations. OHR Pharmaceutical, Inc. is headquartered in New York, New York. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/07/12 21:55
End of Day Share Price2019/07/12 00:00
Earnings2019/03/31
Annual Earnings2018/09/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.